(Q39343506)

11 September 2017

1 reference

title

Angiotensin-converting enzyme inhibitors: past, present, and bright future (English)

1 reference

11 September 2017

C R Edwards

1

1 reference

PubMed ID

2856956

11 September 2017

P L Padfield

series ordinal

2

1 reference

PubMed ID

2856956

11 September 2017

language of work or name

English

0 references

publication date

1 January 1985

1 reference

11 September 2017

1 reference

11 September 2017

1

1 reference

11 September 2017

8419

1 reference

11 September 2017

30-34

1 reference

CAPTOPRIL IN THE TREATMENT OF CLINICAL HYPERTENSION AND CARDIAC FAILURE

11 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Design of Specific Inhibitors of Angiotensin-Converting Enzyme: New Class of Orally Active Antihypertensive Agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

A new class of angiotensin-converting enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Differences in response to the peptidyldipeptide hydrolase inhibitors SQ 20,881 and SQ 14,225 in normal-renin essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Effect of angiotensin-converting enzyme inhibition on circulating and local kinin levels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Role of kinins in the acute antihypertensive effect of the converting enzyme inhibitor, captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Relationships between the kallikrein-kinin and prostaglandin systems

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Angiotensin-converting enzyme inhibition and prostaglandins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Effects of an angiotensin-converting enzyme inhibitor (captopril) on blood pressure in anephric subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Interaction of angiotensin-converting enzyme inhibitors with the function of the sympathetic nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Autonomic and baroreflex function after captopril in hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Role of sympathetic nervous system activity in the blood pressure response to long-term captopril therapy in severely hypertensive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Haemodynamic, hormonal, and electrolyte responses to captopril in resistant heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Increase in plasma aldosterone during prolonged captopril treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Enalapril in the treatment of hypertension with renal artery stenosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Clinical use of an orally acting converting enzyme inhibitor: captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Captopril-Induced Functional Renal Insufficiency in Patients with Bilateral Renal-Artery Stenoses or Renal-Artery Stenosis in a Solitary Kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Captopril/diuretic combinations in severe renovascular disease: a cautionary note

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Repeated renal failure with use of captopril in a cystinotic renal allograft recipient

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Increased renal plasma flow in long-term enalapril treatment of hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Reactive Hyperreninemia in Renovascular Hypertension After Angiotensin Blockade with Saralasin or Converting Enzyme Inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Splint renal function after captopril in unilateral renal artery stenosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Captopril in the management of hypertension with renal artery stenosis: its long-term effect as a predictor of surgical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Long-term converting-enzyme inhibition as a guide to surgical curability of hypertension associated with renovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Combined treatment of severe intractable hypertension with captopril and diuretic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Acute and chronic treatment of severe and malignant hypertension with the oral angiotensin-converting enzyme inhibitor captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Clinical experience with captopril in the treatment of severe drug-resistant hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Effect of angiotensin II and converting enzyme inhibitor (captopril) on blood pressure, plasma renin activity and aldosterone in primary aldosteronism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Increased Adrenal Sensitivity to Angiotensin II in Idiopathic Hyperaldosteronism*

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Comparison of captopril and hydrochlorothiazide alone and in combination in mild to moderate essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

ANTIHYPERTENSIVE EFFECT OF THE NEW ORAL ANGIOTENSIN CONVERTING ENZYME INHIBITOR "MK-421"

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

A comparative pilot study of enalapril, a new converting enzyme inhibitor, and hydrochlorothiazide in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Antihypertensive Therapy with MK 4211

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Optimal dose of captopril in hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Improvement of chronic congestive heart-failure by oral captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Effects of captopril in acute and chronic heart failure. Correlations with plasma levels of noradrenaline, renin, and aldosterone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Sustained Effectiveness of Converting-Enzyme Inhibition in Patients with Severe Congestive Heart Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Captopril in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Long-term captopril therapy in congestive heart failure: serial hemodynamic and echocardiographic changes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Vasodilator therapy of severe congestive heart failure: The special importance of angiotensin-converting enzyme inhibition with captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Hemodynamic and hormonal responses during captopril therapy for heart failure: acute, chronic and withdrawal studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Determinants of acute and long-term response to converting enzyme inhibitors in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

A placebo-controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

The renin-angiotensin system in refractory heart failure: clinical, hemodynamic and hormonal effects of captopril and enalapril

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Captopril in primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Captopril as treatment for patients with pulmonary hypertension. Problem of variability in assessing chronic drug treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Low-dose captopril in chronic heart failure: acute haemodynamic effects and long-term treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Long-term treatment of bartter's syndrome with captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Captopril and resistant ascites

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Reversal of Scleroderma Renal Crisis for More Than Two Years in a Patient Treated with Captopril

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Relief from digital vasospasm by treatment with captopril and its complete inhibition by serine proteinase inhibitors in Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Captopril-Induced Skin Eruptions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Captopril-associated neutropenia. Who is at risk?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Successful reintroduction of captopril following neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Reversible leucopenia associated with angiotensin-converting-enzyme inhibitor MK 421

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Neurological dysfunction in two patients receiving captopril and cimetidine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Fatal Stevens-Johnson syndrome in a patient on captopril and allopurinol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Potent new inhibitors of human renin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2885%2990975-4

7 January 2021

10.1016/S0140-6736(85)90975-4

Identifiers

DOI

1 reference

11 September 2017

1 reference

PubMed ID

2856956